[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].
Clinical studies showed that paclitaxel is active as single agent and in combination chemotherapy for the management of metastatic breast cancer. A variety of doses and administration schedules have been evaluated in phase II and III trials. Weekly administration of paclitaxel which is generally well tolerated increases the therapeutic index (efficacy/safety) resulting from anti-angiogenic and pro-apoptotic effects.
Campone
Mario
M
Service d'oncologie, Centre René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain Cedex.
Fumoleau
Pierre
P
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000068878:Trastuzumab; D017239:Paclitaxel
Le paclitaxel en administration hebdomadaire dans le traitement du cancer du sein métastique: du rationnel à la pratique.